Predicting outcomes in pediatric nephrotic syndrome
Part of Blood & lymphatic, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study is looking for children newly diagnosed with idiopathic nephrotic syndrome (a kidney condition that causes swelling and protein in the urine) who have not yet been treated. Researchers will study their blood and genes to find better ways to predict how the disease will progress and which treatments might work best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have a diagnosis of idiopathic nephrotic syndrome (kidney disease that causes swelling and protein in the urine).
- They must have a lot of protein in their urine (more than 2 mg of protein for every mg of creatinine).
- They must have low blood protein (albumin less than 3.0 g/dL) and swelling (edema).
- They must not have received any treatment for nephrotic syndrome before joining the study.
- Your child must be between 1 and 18 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks children with nephrotic syndrome whose kidney disease does not respond to usual treatments. It aims to collect information and samples to better understand resistant forms of the condition.
This trial tests if a hormone called ACTH can help children with nephrotic syndrome who have frequent relapses or need steroids to stay in remission. It aims to find a treatment that may reduce the need for steroids and prevent relapses.
This study uses interviews to understand how swelling from nephrotic syndrome affects daily life for children and their caregivers. It may help researchers design better care by capturing the patient and parent perspective.
This study tests an injection (SG301) that targets a protein called CD38 to help children whose nephrotic syndrome keeps coming back or depends on steroids. The goal is to see if the treatment can reduce relapses and the need for steroids.
This trial tests if dupilumab can help children with nephrotic syndrome who still have relapses despite standard treatments. It aims to find a better way to control the disease and reduce steroid side effects.
This trial studies whether rituximab alone can help children with new-onset idiopathic nephrotic syndrome. It compares the treatment approach in order to see if it improves kidney recovery and reduces disease activity.
Hear when a new Nephrotic Syndrome in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.